Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 16Neoplasms 6Prostate Cancer Metastatic 4Solid Cancer 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer, MCRPC 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Castrate-Resistant Prostate Cancer 1Advanced Solid Tumor 1

Interventions

enzalutamide 5Prednisone 5cabazitaxel 4Docetaxel 3Abiraterone Acetate 3fludrocortisone acetate 1Zuclomiphene 1XRP6258 1Standard of Care 1Prednisolone 1Midazolam 1LY3023414 1Injections 1Hydrocortisone 1Dexamethasone 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Prostate Cancer Metastatic × cabazitaxel × Clear all
NCT02485691 2022-05-27

CARD

Sanofi

Phase 4 Completed
255 enrolled 21 charts
Genitourinary

Prostate Cancer Metastatic

NCT02379390 2019-06-21

PRIMCAB

Sanofi

Phase 2 Terminated
8 enrolled 8 charts
Genitourinary

Prostate Cancer Metastatic

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed
63 enrolled 13 charts
Genitourinary

Prostate Cancer Metastatic

NCT01254279 2015-01-21

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Sanofi

Phase 3 Completed
984 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡